He succeeds Anders Karlsson, who has served in the position since August 2022.

Viktor Drvota

Viktor Drvota, M.D., Ph.D., Associate Professor in Cardiology, has over 20 years of venture capital experience spanning numerous investments, significant fundraising campaigns, IPOs, and successful exits. As Head of Life Sciences at SEB Venture Capital (2002–2016), he served on the boards of several prominent biotech and medtech companies. Prior to his venture capital career, Dr. Drvota worked as a Senior Consultant and Associate Professor in Cardiology at Karolinska Institutet/Hospital. His extensive background encompasses both preclinical and clinical research in drug development and medical device innovation. He is currently the CEO of Karolinska Development and will continue in this role alongside his new position as CEO of Umecrine Cognition on a 50/50 basis.

“Umecrine Cognition and Karolinska Development are two well-functioning organizations with experienced and highly specialized teams. This dual leadership arrangement represents a cost-effective approach to drive both companies forward, and I look forward to focusing more intensively on one of Karolinska Development’s largest holdings while serving both organizations. I would like to thank Anders Karlsson for his contributions over the past few years—not least for his very valuable achievements in elevating Umecrine Cognition’s international visibility while preparing for commercial partnerships,” says Viktor Drvota, incoming CEO of Umecrine Cognition.